Studies seeking the development of highly potent and selective PLA2 inhibitors could contribute to the development of novel therapeutic agents for the treatment of inflammatory pain, including arthritis and envenomation-induced pain. This evidence concerns the gene PLA2G2A and arthritic joint disease.